Who is sponsoring NCT03768518?

NCT03768518 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03768518?

Interventions in NCT03768518: 68Ga-exendin-4 PET/CT.

What condition does NCT03768518 study?

NCT03768518 studies Congenital Hyperinsulinism.

Is NCT03768518 still recruiting?

NCT03768518 is currently status unknown. Last updated 7 December 2018.

Last reviewed 2018-12-07 · How we verify

NCT03768518: GLP-1-CHI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GLP-1 Receptor Expression in CHI

Status unknown Last updated 7 December 2018

What this trial tests

trial testing 68Ga-exendin-4 PET/CT in Congenital Hyperinsulinism in 40 participants. Status unknown.

Timeline

7 February 2018

Primary endpoint
1 February 2019

1 February 2019

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	7 February 2018
Primary completion	1 February 2019
Estimated completion	1 February 2019
Sites	1 location across Netherlands

Drugs / interventions tested

68Ga-exendin-4 PET/CT

Conditions studied

Congenital Hyperinsulinism — all drugs for Congenital Hyperinsulinism →

Sponsor

Radboud University Medical Center

Who can join

Under 16, any sex, with Congenital Hyperinsulinism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging.
Boss M, Buitinga M, Jansen TJP, Brom M, et al · · 2020 · cited 30× · PMID 31519801 · DOI 10.2967/jnumed.119.228627
68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.
Boss M, Rottenburger C, Brenner W, Blankenstein O, et al · · 2022 · cited 25× · PMID 34215672 · DOI 10.2967/jnumed.121.262327
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.
Velikyan I, Eriksson O. · · 2020 · cited 24× · PMID 31903131 · DOI 10.7150/thno.38366
Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
Boss M, Bos D, Frielink C, Sandker G, et al · · 2020 · cited 13× · PMID 32385165 · DOI 10.2967/jnumed.119.238998
Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW.
Boss M, Bos D, Frielink C, Sandker G, et al · · 2020 · cited 7× · PMID 31924726 · DOI 10.2967/jnumed.119.234542
Clinical application of 18F-DOPA PET/TC in pediatric patients.
Masselli G, Casciani E, De Angelis C, Sollaku S, et al · · 2021 · cited 6× · PMID 34079636
PET/CT in congenital hyperinsulinism: transforming patient's lives by molecular hybrid imaging.
Pizzoferro M, Masselli G, Maiorana A, Casciani E, et al · · 2022 · cited 2× · PMID 35535120

Verify or expand the search:

Other recruiting trials for Congenital Hyperinsulinism

Currently open trials in the same condition.

NCT06208215 — RZ358 Treatment for Congenital Hyperinsulinism · Phase 3 · active not recruiting
NCT04732416 — HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) · Phase 2 · recruiting
NCT03941236 — Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism · Phase 3 · active not recruiting
NCT04205604 — 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism · Phase 2 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03768518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 7 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03768518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing